key: cord-0022839-qkpoid82 authors: Ji, Rong; Ma, Lixiang; Chen, Xinyu; Sun, Renqiang; Zhang, Li; Saiyin, Hexige; Wei, Wenshi title: Characterizing the distributions of IDO-1 expressing macrophages/microglia in human and murine brains and evaluating the immunological and physiological roles of IDO-1 in RAW264.7/BV-2 cells date: 2021-11-04 journal: PLoS One DOI: 10.1371/journal.pone.0258204 sha: 5dedf8491a289877f1ed0aaa077b112c266be7de doc_id: 22839 cord_uid: qkpoid82 Indoleamine 2,3-dioxygenase 1 (IDO-1) is an immunosuppressive enzyme expressed in the placenta, neoplastic cells, and macrophages to reject T cells by converting tryptophan into kynurenine. However, the role of IDO-1 in brain immunity, especially in the meninges, is unclear. We aim to elucidate the distribution pattern of IDO-1+ macrophages/microglia in the human brain tissues, human glioblastoma, APP/PS1 mouse brains, and quinolinic acid model brains and explore the physiological and immunological roles of IDO-1+ macrophages/microglia. Here, we find that both human and mouse macrophages/microglia of the perivascular and subarachnoid space and in glioblastoma (GBM) expressed IDO-1 but not macrophages/microglia of parenchyma. Using IDO-1 inhibitors including 1-MT and INCB24360, we observed that inhibiting IDO-1 reduced the cellular size and filopodia growth, fluid uptake, and the macropinocytic and phagocytic abilities of human blood monocytes and RAW264.7/BV-2 cells. Inhibiting IDO-1 with 1-MT or INCB24360 increased IL-1β secretion and suppressed NLRP3 expression in RAW264.7/BV-2 cells. Our data collectively show that IDO-1 expression in perivascular and meninges macrophages/microglia increases cellular phagocytic capacity and might suppress overactivation of inflammatory reaction. Indoleamine 2,3-dioxygenase 1 (IDO-1), an immunosuppressive metabolic enzyme, prevents maternal T cell-driven immune rejection during pregnancy by metabolizing tryptophan into kynurenine [1] . IDO suppress T-cell proliferation and natural killer cells, promotes regulatory T-cell (Treg) and myeloid-derived suppressor cell (MDSC) development via tryptophan depletion and kynurenine production, and prevents the overactivation of the immune response [2] [3] [4] . Meninges, which cover brain parenchyma, are populated by immune sentinels, including macrophages and dendritic cells, mast cells, T cells, and B cells [5] [6] [7] . However, the brain parenchyma rejects T-cell infiltrates [8] . The barriers formed by the pia matter and glia limitans are thought to contribute to T-cell rejection. Whether immune cells in the meninges are involved in T-cell rejection by the parenchyma is unknown. Although debated for many years, activated macrophages/microglia are classified into the M1 or M2 phenotype for functional annotation [9] . The M1 macrophage is proinflammatory, while the M2 macrophage is anti-inflammatory [9] [10] [11] . M1 macrophages increase iNOS and secrete proinflammatory factors, such as TNF-α, IL-1β, IL-6, superoxide, nitric oxide, reactive oxygen species, and proteases [11, 12] . IDO-1 is reported to be highly expressed in M1 macrophages and drives macrophages to express M2 markers such as IL-10 and CXCR4 [13] . IL-4, IL-13, and IL-10 are induced to form typical M2 macrophages [12] . M2 macrophages engulf cellular debris or misfolded proteins, facilitate extracellular matrix (ECM) reconstruction and tissue repair, and support neuronal survival by secreting neurotrophic factors [14, 15] . In viral infections, inhibiting IDO-1 in macrophages leads to a surge in the secretion of proinflammatory cytokines such as IFN-γ, IL-1β, IL-6, and TNF-α [16] . IDO-1 -/mice also secrete type I IFN in LP-BM5 infection and restrict viral replication [17] . If the brain parenchyma utilizes IDO-1 to form an immune barrier and reject T-cell infiltrates, it has not yet been reported. The microglia database (http://research-pub.gene.com/BrainMyeloidLandscape) has shown that in Alzheimer's disease (AD) and Huntington's disease (HD) patients and murine neurodegenerative models (APP/PS1 and PS2/APP), microglia do not upregulate IDO-1, but the microglia in glioblastoma, murine ischemia, cuprizone and LPS models exhibited upregulated IDO-1 [18] . IDO-1 expression in microglia does not depend on aging in either healthy murine models or humans. Isolated human monocytes from the brain expressed a higher level of IDO-1 compared to microglia. Nonparenchymal macrophages in the perivascular space, subdural meninges, and the choroid plexus partially or mainly originate from monocytes [18] . These data provided us with the idea that IDO-1+ might preferentially reside in perivascular space, meninges, and the choroid plexus. In this work, we detected IDO-1 expression in murine neurodegenerative models and human brain tissue macrophage/microglia and inhibited IDO-1 activities with 1-MT and INCB24360 from testing the roles that IDO-1 plays in macrophage/microglia physiological and immunological activities. Here, we show that IDO-1 is exclusively expressed in macrophage/microglia of the perivascular space, subarachnoid space, and glioblastoma but not in the parenchymal microglia of the brain in humans or murine models. Inhibiting IDO-1 with 1-MT or INCB24360 significantly affects physiological and immunological behavior but not the migration or proliferation of macrophages/microglia, indicating that IDO-1-expressing macrophages in the brain are distinct with the intensive phagocytic ability and lower proinflammatory activity. The study's human sample ethics were approved by the Human Ethics Committee of Huashan Hospital at Fudan University (Approval Series Number, 2018-310). Dr. Li Li from Huashan Hospital collected the freshly surged brain samples from GBM patients after a pathologist check, fixed them by 4% PFA, and sectioned them for immunostaining. All mice were cultured in the animal culturing conditions with air conditioning at the School of Basic Medical Science of Fudan University Animal Cores. All animal procedures were reviewed and approved by the School of Basic Medical Science of Fudan University and Use Committee (Approval Series Number, 2020-0306-002). All mice freely access enough food and sterilized water. A maximum of 5-6 mice was maintained per cage. The infection or injury after surgery were monitored by the veterinarians at the animal cores daily. Mice were deeply anesthetized with isoflurane and perfused by 4% PFA for collecting the brain for immunostaining. 10-month-old APP/PS1 mice were purchased from SLAC. Quinolinic acid models were constructed by following our previously described protocols [19] . After three weeks of quinolinic acid injection to the striatum, the mouse brains were harvested for staining. Human peripheral blood monocyte isolation and culture. 10 mL of blood were drawn from a healthy male, and the monocytes were isolated by Solarbio Human Blood Monocyte Isolation Kit (P8680, Solarbio, China). The isolated monocytes were plated in 24 well's dishes that contain a poly-o-nithine coated cell culturing slide and then cultured 37˚C incubator with 5% CO 2 . Culture Collection) were maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS, Gibco, Carlsbad, CA, USA) in 37˚C/ 5% CO2. Contamination-free cell lines were ensured through testing with a mycoplasma PCR detection kit (BioThrive, Myco-P-20, Shanghai, China). After 5-6 passages, cells were used for experiments. Human isolated blood monocytes, RAW264.7 and BV-2 cells were separately incubated with IFN-γ, 1-MT, and INCB24360 for 24 hours. The inhibition of IFN-γ-induced IDO-1 was accomplished as follows: After incubating cells with IFN-γ for 12 hours, 1-MT/INCB24360 was added to the culture medium without removing IFN-γ and then incubated for another 12 hours. RAW264.7 cells were separately incubated with MCC950 and oridonin for 24 hours to inhibit NLRP3 inflammasome. The doses of the treatment agents were as follows: IFN-γ, 20 ng/mL (interferon-γ, mouse, Sigma, USA), 1-MT, 20 μM (26988-72-7, Sigma, USA), INCB24360, 20 μM (S7910, Selleck, Shanghai, China), MCC950, 10 μM (inh-MCC, Invivogen, USA), oridonin, 2 μM (Dr. RB Zhou Hefei, China). After treatments, the cells were digested with 0.25 Trypsin EDTA, stained by PI and a Flow Cytometry (BD FACSCalibur). The cells were lysed in ice-cold RIPA buffer supplemented with phosphatase inhibitor PMSF for 30 min. The supernatant's protein concentration was measured by a BCA assay kit (PD-BCA-125, BioThrive, Shanghai, China). Proteins (25 μg) were loaded in 12% gels for SDS-PAGE electrophoresis, and then, the proteins were transferred from the gel to PVDF membranes (Millipore, MA, USA). The membranes were blocked with 5% skim milk in TBST (PBS and 0.1% Tween), and incubated at 4˚C overnight with antibodies. After incubation with primary antibodies, the membranes were rinsed with TBST 3 times for 5 min each time and then incubated with species-specific horseradish peroxidase-conjugated secondary antibodies (1:5000, Santa Cruz, Germany) for 60 min at room temperature. After 3 washes with TBST for 10 min each time, the membranes were developed with a super-sensitive enhanced chemiluminescence substrate kit (Biothrive Ltd, ECL-P-100, Shanghai, China) for visualization with a Tanon-4600 imaging system. The following antibodies were used: rabbit anti-iNOS (1:500, ab3523, Abcam, USA), rabbit anti-CD206 (1:500, BM4881, Boster Biological Technology, CA, USA), rat anti-IDO and rabbit anti-IDO (1:500, 654002, BioLegend, San Diego, CA, USA), rabbit anti-IDO (HPA023149, Thermo Scientific, Lafayette, CO, USA), mouse anti-NLRP3 (1:1000, AG-20B-0014, Adipogen, CA, USA), rabbit anti-caspase-1 (1:500, 3866S, Cell Signaling Technology, MA, USA), rabbitanti-S6K (polyclonal, AF8962, EZ-press RNA Purification Kit (B0004DP, USA) was used to extract total RNA by following the manufacturer's protocol. Verso cDNA kit (Thermo Scientific, Lafayette, CO, USA) is applied to cDNA reverse transcription. Quantitative real-time PCR was performed on a Bio-Rad Cx96 Detection System (Bio-Rad, USA) using an SYBR green PCR kit (Applied Biosystems, USA). Primers: 1; iNOS, forward primer (5'-3')GGAGTGACGGCAAACATGACT, reverse primer(5'-3')TCGATGCACAACTGGGTGAAC; 2; CD206, forward primer (5'-3')CTCAACCCAA GGGCTCTTCTAA, reverse primer(5'-3')AGGTGGCCTCTTGAGGTATGTG; 3; TNF-α, forward primer (5'-3')CTGTGAAGGGAATGGGTGTT, reverse primer(5'-3')GGTCACTGTCCCAGCATC TT; 4; Arg-1, forward primer(5'-3')CTCCAAGCCAAAGTCCTTAGAG, reverse primer(5'-3') GGAGCTGTCATTAGGGACATCA; 5; NLRP3, forward primer(5'-3')ATGCTGGCTTCGACATCT CCT, reverse primer(5'-3')GTTTCTGGAGGTTGCAGAGC; 6; Caspase-1, forward primer(5'-3') AGATGCCCACTGCTGATAGG, reverse primer(5'-3')TTGGCACGATTCTCAGCATA; 7; GAPDH, forward primer(5'-3')ATACGGCTACAGCAACAGGG, reverse primer(5'-3') GCCTCTCTTGCTCAGTGTCC. Immunostaining was performed as previously described. Briefly, cells were fixed with 4% paraformaldehyde (PFA), incubated with primary antibody overnight, and incubated with fluorescent secondary antibodies and DAPI for 1 hour. After staining, slides were mounted in medium and observed by microscopy. The following antibodies were used: rabbit anti-iNOS . Images were obtained using a Leica SP8 confocal microscope (Leica Microsystems, Japan). Cell counting and morphological analyses were performed using Fiji (ImageJ) software. The supernatants of RAW264.7 and BV2 cells were collected to detect the level of interleukin-1β (IL-1β) and interleukin-18 (IL-18). An enzyme-linked immunosorbent assay kit (MeiLian, Shanghai, China) was used according to the manufacturer's instructions. Briefly, the samples were diluted to 1:1 by a standard sample diluent, add 50 μl standard samples and 50 μl detecting samples to the wells, and then supplement the wells with 50 μl of biotin-labeled IL-1β or IL-18 antibodies. After mixing, the wells were incubated at 37˚C for 1 h. Discard the liquid, wash the wells for 3 times, add 80 μl streptavidin-conjugated HRP to each well, and incubate at 37˚C for 30 min, rinse the wells with the washing solutions for 3 times. After washing, add 50μl substrate to each well, incubate at 37˚C for 10 min, stop the reaction by 100 μl termination buffer, and read OD values by 450nm. Cells were suspended in serum-free DMEM and placed in a 150 μl (E5/ml) cell suspension in the upper chamber of a Transwell apparatus. Then, 800 μl of DMEM containing 10% FBS was added to the lower chamber. After incubating the RAW264.7 cells for 48 h or BV-2 cells for 24 h, the upper Transwell chambers were removed, and the culture medium in the upper chambers was removed by aspiration. The cells in the chambers were fixed with 4% PFA for 15 min, washed three times with PBS, and then stained in the chambers with crystalline violet solution for 30 min. After staining, the upper layer cells were gently swabbed with a cotton swab moistened in PBS, rinsed with PBS three times and dried for use in microscopy. Edu assay (Invitrogen) was performed by following the supplier's protocol. After drug treatments, an Edu working solution (10 mM, 1:2000, with green fluorescence) was added to the medium and then incubated for 12 h. After incubation, the cells were fixed with 4% PFA for 20 min, rinsed with PBS, permeabilized with 0.2% Triton X-100 for 20 min, and then added to freshly prepared Click-iT™ reaction solution and incubated for 30 min. After washing, the cells were mounted on slides for visualization by microscopy. A Leica SP8 microscope (Leica, German), Structured illumination microscopy (SIM) (Nikon, Japan) and 880 confocal micros-copy (ZEISS, Jena, Germany) was used to scan all images. ImageJ software (Fiji, NIH, Bethesda, MD, USA) was used to count cells and perform morphological analyses. Imaris 9.5 (Bitplane AG, Zürich, Switzerland) was used for the particle size analysis and figure display. SPSS version 21.0 (SPSS Inc, Chicago, IL, USA) and GraphPad software were used for data analysis. One-way ANOVA and t-test were used to test the differences. To see if the IDO-1+ macrophages/microglia preferentially reside in specific sites in murine model and human brains, we adopted a thick-section staining method to localize IDO-1+ macrophages/microglia in the human brain, human GBM tissues, and the brains from the APP/ PS1 mouse and quinolinic acid models with IBA-1 or GFAP and IDO-1 antibodies. The results showed a few IDO-1+ microglia/macrophages with small bodies and few processes in the brain parenchyma and microglia with larger bodies and longer processes not expressing IDO-1 in the brain parenchyma ( Fig 1A- i and 1A-ii). We also observed a considerable number of IDO-1+ microglia/macrophages in the vascular lumen, vascular wall, and perivascular space (Fig 1A- ii) and subarachnoid space in the human brain tissues (Fig 1A- iii and 1B). However, GFAP + astrocytes did not express IDO-1 ( Fig 1C) . In the tumor region and the region close to tumors, we observed that multiple IDO-1+ microglia/macrophages also closely surrounded IDO-1+ macrophages/microglia in meninges blood vessels and appeared in the vascular walls or lumen ( Fig 1D) . Consistent to other observations [20] , we also observed that some brain neoplastic cells are highly expressed IDO-1 ( Fig 1E) . To see IDO-1+ expression patterns in the microglia of murine neurodegenerative models, we stained APP/PS1 mouse and quinolinic acid model brains with anti-IDO-1 and anti-IBA-1 antibodies and found that IDO-1 is not expressed in the microglia of the cortex, hippocampus or striatum in the quinolinic acid injury model brains (Fig 1F-i) or in the activated microglia surrounding amyloid deposits in the APP/PS1 mouse hippocampus and cortex (Fig 1G-i) . We observed a significant fraction of microglia in the subarachnoid space and the choroid plexus of the third ventricle highly expressed IDO-1 (Fig 1F- ii and 1G-ii). The vascular endothelial cells, including capillaries and small arteries, expressed IDO-1 in both models. These data implied that IDO-1+ macrophages/microglia might have distinct physiological and immunological properties. To test how IDO-1 effects macrophage/microglia activities, we treated RAW264.7 and BV-2 cells with 20 ng/mL IFN-γ to increase IDO-1 levels and used 20 μM 1-MT and 20 μM INCB24360 to inhibit IDO-1 activity for 24 h. We detected CD206, an M2 marker, iNOS, an M1 marker, and IDO-1 by western blotting. Consistent with other findings [21], IFN-γ treatment increased IDO-1 and iNOS expression in the RAW264.7 and BV-2 cells (Fig 2A and S1A Fig) . Inhibiting endogenous IDO-1 with INCB24360 or 1-MT reduced iNOS levels but did not affect CD206 in the RAW264.7 or BV-2 cells, and the effects of INCB24360 were more significant than those of 1-MT (Fig 2A and S1A Fig) . We also detected M1/M2 markers, including iNOS, TNF-α, CD206, and Arginase 1 (Arg1) by qRT-PCR, and we found that INCB24360 decreased iNOS and TNF-α RNA in the RAW264.7 and BV-2 cells (Fig 2B and S1B Fig); 1-MT treatment decreased iNOS and TNF-α RNA levels in the BV2 cells but not in the RAW264.7 cells (Fig 2B and S1B Fig) . Interestingly, both 1-MT and INCB increased the CD206 and Arg-1 RNA levels in the RAW264.7 cells. 1-MT did not affect CD206 RNA in BV-2 cells; both 1-MT and INCB did not affect the Arg-1 in BV-2 ( Fig 2B and S1B Fig) . Immunofluorescence staining of RAW264.7 and BV-2 cells treated with INCB24360 and 1-MT revealed that iNOS expression was significantly decreased in INCB24360 groups but CD206 was not changed compared to the levels in the control group ( Fig 2C and S1C Fig) . The data indicate that IDO-1 might induce an increase in M1-like macrophages/microglia in the brain. Non-polarized RAW264.7 cells are small and round with few processes [22] . When polarized, RAW264.7 grow large and round with a pancake-like shape, representative of the M1 phenotype, or they become slimmer cells with longer processes, representative of the M2 phenotype M1 macrophages showed multiple filopodia that facilitate the phagocytosis of fluid or foreign substances, including inorganic particles [23] . We treated RAW264.7 and BV-2 cells with IFN-γ, 1-MT, or INCB24360 for 24 h, fixed the cells and stained them with phalloidin Alexa-488, an actin-binding dye, and DAPI. We then observed that the macrophages treated with IFN-γ formed a ruffled border with abundant filopodia (Fig 3B and S2B Fig). INCB24360treated macrophages showed fewer filopodia than the control, IFN-γ, and 1-MT RAW264.7 and BV-2 cell groups (Fig 3B and S2B Fig). The cellular perimeter and filopodia density data showed that the 1-MT and INCB24360 treatment did not change the cellular perimeter but decreased the filopodia density on the cellular membrane (Fig 3B and S2B Fig) . Collectively, these findings implied that inhibition of IDO-1 preferentially blocks cellular size increases and filopodia growth. To determine whether, in addition to a decrease in iNOS and filopodia and the acquisition of a ruffled cellular border, INCB24360 treatment also reduces the phagocytosis ability of the RAW264.7 and BV-2 cells, we administered TMR-dextran to RAW264.7 and BV-2 cells after treating them with IFN-γ, 1-MT, and INCB24360 for 24 h. After 1 h of TMR-dextran treatment, we fixed the cells and counterstained them with phalloidin-Alex-488 and DAPI, and we found that INCB24360 treatment significantly reduced DMR-dextran uptake compared to the amount internalized by the control and IFN-γ+ RAW264.7 cell groups compared to the BV-2 cell groups (Fig 4A-4D) . Macropinocytosis, which depends on membrane ruffling, is the mechanism by which macrophages internalize large amounts of extracellular fluid [24] . The decrease in filopodia on the ruffled border after IDO-1 inhibition implied that IDO-1 might enhance macropinocytosis. The macropinosome ranged from 0.2 μm to 5 μm in diameter [25] . The vesicles, which are larger than 0.75 μm, have been identified as apparent macropinocytic vesicles in DTR-dextran uptake assays performed in some studies [26] . We found that INCB24360 treatment decreased the number of phagocytic vesicles larger than 0.75 μm in RAW264.7 and BV-2 cells (Fig 4E and 4F) . Macrophages, especially tissue-resident macrophages, can phagocytize foreign-derived particulates such as alum and silica. M1 macrophages can also phagocytize foreign-derived particulates [27, 28]. We treated RAW264.7 and BV-2 cells with Latex beads, a spherical polymer particle, and fluorescence red, after incubating the cells with IFN-γ, 1-MT, or INCB24360 for 24 h. After fixing the cells with 4% PFA, we analyzed the phagocytized Latex beads and observed that 1-MT and INCB24360 treatment slightly decrease the Latex beads uptake by the BV-2 cells compared to the control cells, but the decrease was not statistically significant ( Fig 4G) . In contrast to M2 macrophages, M1 macrophages show low motility [29, 30]. We used 1-MT and INCB24360 to test their effects on the migration and proliferation of macrophages in a Transwell migration assay and in an Edu staining assay and Flow cytometry to test cell proliferative potential. Consistent with the formation of M1 macrophages, the results showed that IFN-γ treatment dramatically decreased the migration ability of the RAW264. To determine whether IDO-1 inhibitors affected IFN-γ-induced M1 or M2 markers, we treated RAW264.7 and BV-2 cells with IFN-γ for 12 h, and then we added 1-MT or INCB24360 for 24 h. Both 1-MT and INCB24360 significantly decreased iNOS levels but did not change CD206 levels in the IFN-γ-treated RAW264.7 cells; a greater decrease in iNOS was observed in the INCB24360 group (Fig 5A) . However, neither 1-MT nor INCB24360 changed the iNOS and CD206 expression in the IFN-γ-treated BV-2 cells (S4A Fig). We also detected iNOS, TNF-α, CD206, and Arg1 RNA levels by RT-PCR in the four cell groups and found that INCB24360 treatment reduced the iNOS and TNF-α RNA levels in the IFN-γ-induced RAW264.7 and BV-2 cells (Fig 5B and S4B Fig). INCB24360 treatment significantly increased the transcription level of CD206 RNA but not Arg1 RNA in the IFN-γ-treated RAW264.7 cells, but 1-MT treatment did not significantly affect the transcription of iNOS, TNF-α, CD206, or Arg1 genes (Fig 5B) . In agreement with the western blot analysis results, immunofluorescence staining results showed that iNOS expression significantly decreased in the IFN-γ-treated cells treated with INCB24360 or 1-MT compared to the IFN-γ-treated RAW264.7 and BV-2 cells (Fig 5C and S4C Fig) . Further, 1-MT treatment significantly increased CD206 expression in the IFN-γ-treated RAW264.7 cells, while 1-MT and INCB24360 increased CD206 expression in the IFN-γ-induced BV-2 cells (Fig 5C and S4C Fig) . To determine whether IDO-1 inhibitors also inhibit IFN-γ-induced cellular size and filopodia growth, we treated RAW264.7 and BV-2 cells with IFN-γ for 12 h and then added 1-MT or INCB24360 for 24 h. After imaging, we found that INCB24360 treatment not only decreased the total number of polarized RAW264.7 cells (Fig 6A) and BV-2 cells driven by IFN-γ (S5A Fig) , but INCB24360 treatment preferentially decreased the number of IFN-γinduced M1 RAW264.7 and BV-2 cells (Fig 6A and S5A Fig). Interestingly, INCB24360 treatment significantly increased the IFN-γ-induced M2 macrophage proportion (Fig 6A and S5A Fig) . Further, 1-MT treatment decreased the number of total IFN-γ-induced polarized macrophages, and this decrease affected M1 or M2 macrophages equally (Fig 6A and S5A Fig) . The findings support the supposition that INCB24360 can reverse IFN-γ-driven M1 macrophage increases. To determine whether IDO-1 inhibitors block IFN-γ-driven ruffled border formation and filopodia growth, we treated RAW264.7 and BV-2 cells with IFN-γ for 12 h, and then added 1-MT or INCB24360 for 24 h, fixed the cells and stained them with phalloidin Alexa-488 and DAPI. Our data showed that INCB24360 inhibited the formation of the IFN-γ-induced ruffled border and filopodia formation in the RAW264.7 and BV-2 cells (Fig 6B and S5B Fig) . Measuring and counting data showed that both 1-MT and INCB24360 treatments significantly inhibited the increase in RAW264.7 cell size induced by IFN-γ (Fig 6B) but did not affect BV-2 cells (S5B Fig) INCB24360 treatment also inhibited the increase in filopodia density on the cellular membrane induced by IFN-γ (Fig 6B and S5B Fig) , but 1-MT treatment did not restrict the increase in filopodia density on the cellular membrane induced by IFN-γ (Fig 6B and S5B Fig) . Inhibiting IDO-1 with INCB24360 or 1-MT reduced both cell size and filopodia growth in the macrophages/microglia. To determine whether 1-MT and INCB24360 can decrease the endocytic and macropinocytic ability induced by IFN-γ, we treated freshly isolated human peripheral blood monocytes, BV-2 and RAW264.7 cells with IFN-γ for 12 h and then treated them with 1-MT and INCB24360 for another 12 h. We then added DTR-dextran to the culture medium. After treating with DTR-dextran for 1 h, we fixed the cells and counterstained them with phalloidin Alex-48h. In human blood monocytes, both INCB24360 and I-MT decreased IFN-γinduced cellular size increase and the TMR-dextran uptake ability (Fig 6C) . INCB24360 decreased the TMR-dextran uptake ability of both the RAW264.7 and BV-2 cells; 1-MT significantly decreased the TMR-dextran uptake ability of the RAW264.7 cells but not of the BV-2 cells (Fig 7A-7D) . We analyzed the DTR-dextran phagocytic vesicles that were larger than 0.75 μm, which is reflective of macropinocytosis, by Imaris9.6 software. The findings indicated that INCB24360 treatment decreased the number of vesicles larger than 0.75 μm phagocytosed by RAW264.7 and BV-2 cells, and 1-MT significantly decreased the number of vesicles larger than 0.75 μm phagocytosed by RAW264.7 cells but not by BV-2 cells (Fig 7E and 7F) . To determine the effect of 1-MT and INCB24360 on macrophage phagocytic ability, we treated RAW264.7 and BV-2 with IFN-γ for 12 h. We added 1-MT or INCB24360 and incubated the cells for 24 h, then introduced Latex beads to the culture medium. After fixing the cells, we analyzed the number of phagocytized Latex beads in the cells and found that INCB24360 and 1-MT treatment significantly decreased the number of Latex beads phagocytosed by BV-2 cells. The number of latex beads phagocytosed by IFN-γ-induced BV-2 cells treated with INCB24360 was significantly lower than that phagocytosed by the untreated IFNγ-induced BV-2 cells. However, the number of latex beads phagocytosed by IFN-γ-induced BV-2 cell treated with 1-MT was not significantly lower than that phagocytosed by untreated IFN-γ-induced BV-2 cells (Fig 7G) . In summary, I-MT and INCB24360, but especially INCB24360, inhibited the endocytic, phagocytic, and macropinocytic ability of IFN-γ-treated macrophages. The NLRP3 inflammasome, a large protein complex, includes NLRP3, ASC, and caspase 1 [31] . The NLRP3 inflammasome is involved in M1 macrophage formation [32] . Curcumin, an IDO-1 inhibitor, suppresses NLRP3 expression in chronic unpredictable mild stress (CUMS) and reduces depression-like behaviors [33] . To determine whether NLRP3 and IDO-1 are coupregulated in macrophages/microglia in vivo, we stained the human brain tissues with anti-IBA-1, anti-IDO-1 and anti-NLRP3 antibodies and observed that IDO-1+ macrophage/microglia in the perivascular space (Fig 8A) . To determine how IDO-1 affects NLRP3 expression, we treated RAW264.7 and BV-2 cells with IFN-γ, 1-MT, and INCB24360 for 24 h. We detected NLRP3 expression by western blotting and found that both 1-MT and INCB24360 decreased NLRP3 but not caspase-1 expression in the RAW264.7 and BV2 cells (Fig 8B) . The decreases in NLRP3 were statistically significant in the INCB24360 and 1-MT groups (Fig 8B) . We also used immunostaining of anti-NLRP3 and anti-iNOS antibodies to detect changes in NLRP3 and iNOS expression. Consistent with immunoblotting and RT-PCR results, INCB24360 treatment significantly decreased NLRP3 expression in the RAW264.7 cells (Fig 8C) and BV-2 cells (S6C Fig). To determine whether 1-MT and INCB24360 can also decrease IFN-γ-induced NLRP3 expression, we also treated RAW264.7 cells with IFN-γ for 12 h, and then added 1-MT or INCB24360 for 24 h to inhibit IDO-1 activity. The data showed that both 1-MT and INCB24360 inhibited IFN-γ-induced NLRP3 expression but not caspase-1 expression ( Fig 8D) . The RT-PCR data also showed that INCB24360 and 1-MT reduced IFN-γ-induced NLRP3 gene transcription in both RAW264.7 and BV-2 cells but did not reduce caspase-1 transcription (Fig 8E and S6F Fig) . We immunostained these treated cells with anti-NLRP3 and anti-iNOS antibodies, and the results of the immunofluorescence staining of RAW264.7 cells were consistent with the protein blotting results (Fig 8F and S6F Fig) . The NLRP3 inflammasome activates caspase 1, which cleaves pro-IL-1β and pro-IL-18, and leads to the secretion of IL-1β and IL-18 [31] . Inhibiting IDO with 1-MT dramatically caused a surge in IFN-γ, IL-1β, IL-6, and TNF-α secretions from the macrophages infected with the influenza virus [9, 16] . To determine whether the decrease in NLRP3 by 1-MT and INCB24360 affects IL-1β and IL-18 secretion, we treated RAW264.7 cells with 20 ng/mL IFNγ, 20 μM 1-MT, and 20 μM INCB24360 for 24 h. We detected IL-1β and IL-18 secretion levels in the medium by ELISA and found that IL-1β and IL-18 levels in the culture medium of IFNγ-, 1-MT-, and INCB24360-treated RAW264.7 and BV-2 cells were significantly increased (S7A and S7B Fig) . Tryptophan deprivation by IFN-γ-induced IDO-1 inhibits mTORC1 kinase, and tryptophan or 1-MT treatment reversed mTORC1 inhibition [2, 34] . To determine whether INCB24360 reverses mTORC1 inhibition, we used an anti-phosphorylated (p) S6K (T389) antibody to evaluate mTORC1 activation levels in RAW264.7 cells. Interestingly, we did not NLRP3 deficiency inhibits the IDO-1 upregulation induced by LPS in the hippocampal microglia [35] . To determine whether NLRP3 inhibition affects endogenous IDO-1 levels in RAW264.7 cells, we suppressed NLRP3 in RAW264.7 cells with MCC950, an inhibitor of NLRP3 by targeting ATP-hydrolysis [36] , and oridonin, a covalent NLRP3 inhibitor [37] . After exposing RAW264.7 cells to MCC950 or oridonin for 24 h, we detected NLRP3 and IDO-1 expression (S7E Fig), and found that inhibiting NLRP3 with oridonin and MCC950 increased IDO-1 expression in the RAW264.7 cells (S7F Fig). Our data indicate that NLRP3 and IDO-1 might co-regulate each other in macrophages. infiltrates and diminishes the immune response [38, 39] . We showed that IDO-1+ macrophages/microglia reside in the perivascular and subarachnoid spaces at the brain parenchyma interface. Using IDO-1 inhibitors, we found that IDO-1 enhanced macrophage/microglia endocytic, phagocytic, and macropinocytic capacities via increases in cell size and filopodia growth. Inhibition of IDO-1 in macrophages/microglia reduced NLRP3 expression but increased the secretion of IL-1β. Consistent with a lower migrating ability of M1 macrophages and morphometric analysis [29], IFN-γ treatment significantly reduced the migration of RAW264.7 and BV-2 but not 1-MT, INCB24360. The multiple filopodia of macrophage in IFN-γ treatment might contribute to phagocytic or endocytic ability but not migrating. Our findings showed that IDO-1+ macrophages/microglia have strong endocytic, phagocytic, and macropinocytic capacities and weaker proinflammatory properties in the meninges. Macrophages/microglia scavenge cellular debris, effete cells, invading microbes, and metabolites in the cerebrospinal fluid (CSF) and parenchyma to maintain homeostasis [5, 7] . The meninges, perivascular, and choroid-plexus macrophages patrol the CSF to surveil waste and invasion [5, 7] . The observation of vascular wall-traversing or vascular luminal IDO-1+ macrophages indicates that some IDO-1+ macrophages might originate from a monocyte, which is consistent with the transcriptome database on macrophages/microglia [18] . In contrast to the meninges with abundant immune infiltrates, T cells are almost absent in healthy brain parenchyma. T-cell infiltration in brain parenchyma is a hallmark of multiple sclerosis (MS) [40] . Ectopic T-cell infiltration is also observed in the parenchyma of Parkinson's and Alzheimer's patients [41] [42] [43] . The only pathway to parenchyma for T cells involves crossing the bloodbrain barrier (BBB) and the pia matter. Thus, whether IDO-1+ macrophages/microglia partially or significantly participate in the rejection of T cells at the brain parenchyma is worth exploring in the future. Consistent with attenuated ruffled border and filopodia formation, inhibiting IDO-1 decreased the endocytic, macropinocytic, and phagocytic abilities of macrophages/microglia. Surprisingly, we also observed that IDO-1+ macrophages in metastatic lymph nodes and tumors possess multiple processes and larger body sizes in pancreatic cancer patients (unpublished data). These observations further support the supposition that IDO-1 is related to large cell size and greater macrophage/microglia phagocytic and macropinocytic abilities. The decrease in endocytic, macropinocytic, and phagocytic ability and iNOS and TNF-ɑ levels after inhibiting IDO-1 showed that IDO-1 drives the formation of M1-like macrophages. IL-1β is a critical proinflammatory cytokine in M1 macrophages [44] . Previous data showed that IDO-1 -/mice suppressed LP-BM5 replication by secreting excessive type I IFN, and 1-MT treatment dramatically led to a surge in IL-1β secretion by macrophages in conjunction with virus-induced inflammation [9, 16, 17] . The enhancement of IL-1β secretion after inhibiting IDO-1 hints at an anti-inflammatory role for IDO-1 in macrophages/microglia. IDO-1 is a downstream enzyme of the NLRP3 inflammasome, and IDO-1 upregulation induced by lipopolysaccharide (LPS) is diminished in the glial cells of Nlrp3 -/mice, including microglia [32, 35] . The inhibition of IDO-1 with curcumin decreased NLRP3 expression [33] . We showed that both 1-MT and INCB24360 reduced endogenous or IFN-γ-induced NLRP3 expression, and inhibiting NLRP3 also increased IDO-1 expression, indicating that the relationship of NLRP3 and IDO-1 is bidirectional, and the direction depends on the activation status of macrophages/microglia. In the future, to what extent IDO-1 expressing microglia/macrophages contribute to immune barriers of the brain parenchyma and if the IDO-1 expressing endothelial cells also contribute to the T cell rejection by parenchyma are worth exploring. Another interesting point is that if IDO-1 deregulation in macrophage/microglia correlated with brain autoimmunity diseases caused by the abnormal entrance of T cells to parenchyma, such as Multiple Sclerosis [45] . Our findings collectively show that IDO-1+ macrophages/microglia in meninges are phagocytes with higher scavenging ability and lower proinflammatory activity, implying that IDO-1+ macrophages/microglia combined with IDO-1 + endothelial cells might be involved in the prevent T cells from the meninges/perivascular space from entering the parenchyma or crossing the BBB and may prevent the overactivation of immune response. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape Advances in Meningeal Immunity Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders Meningeal Immunity and Its Function in Maintenance of the Central Nervous System in Health and Disease Where are we? The anatomy of the murine cortical meninges revisited for intravital imaging, immunology, and clearance of waste from the brain The M1 and M2 paradigm of macrophage activation: time for reassessment Oracles of Health and Disease Macrophage Polarization Macrophage polarization in inflammatory diseases The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells Microglial activation and dopamine terminal loss in early Parkinson's disease Tissue-resident macrophages Drug analog inhibition of indoleamine 2,3-dioxygenase (IDO) activity modifies pattern recognition receptor expression and proinflammatory cytokine responses early during influenza virus infection The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer's Disease Not Evident in Mouse Models Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival Regulation of indoleamine 2, 3-dioxygenase in hippocampal microglia by NLRP3 inflammasome in lipopolysaccharide MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells Discovery of IDO1 Inhibitors: From Bench to Bedside Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases The IL-1 family: regulators of immunity Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System We thank everyone who supported this project and opened their facilities to us after the Covid-19 outbreak so that we could finish this work.